Literature DB >> 21123633

Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery.

Elias K Spanakis1, Themistoklis K Kourkoumpetis, Grigorios Livanis, Anton Y Peleg, Eleftherios Mylonakis.   

Abstract

OBJECTIVE: To assess whether statin therapy decreases the incidence of cultures positive for Candida species among high-risk hospitalized patients with type 2 diabetes mellitus (DM). PATIENTS AND METHODS: We performed a retrospective cohort study analyzing the records of all patients with type 2 DM who were admitted to Massachusetts General Hospital for lower gastrointestinal tract surgery between January 1, 2001, and May 1, 2008. We defined statin exposure as the filling of at least 1 prescription of statins during the 6 months before hospitalization or during the current hospital stay. The primary outcome was a culture positive for Candida species during hospitalization. Clinical information on a wide range of covariates was collected. Logistic regression analysis was used to adjust for possible confounders.
RESULTS: Of the 1019 patients who were eligible for the study, 493 (48%) were receiving statins. A total of 139 patients (14%) had at least 1 culture positive for Candida species during hospitalization. An adjusted multivariate model based on a backward stepwise elimination procedure showed that statin therapy significantly decreased the incidence of cultures positive for Candida species (odds ratio, 0.60; 95% confidence interval [CI], 0.38-0.96; P=.03) with a statistically significant prolonged time to event compared with no statin therapy (adjusted hazard ratio, 0.62; 95% CI, 0.44-0.88; P=.01). The benefit of statins was more prominent in patients with type 2 DM who had greater comorbidities (Charlson Comorbidity Index ≥2) (adjusted odds ratio, 0.47; 95% CI, 0.27-0.79; P=.01).
CONCLUSION: Among patients with type 2 DM who underwent gastrointestinal surgery, use of statins correlated with a decreased incidence of cultures positive for Candida species.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123633      PMCID: PMC2996154          DOI: 10.4065/mcp.2010.0447

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  27 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System.

Authors: 
Journal:  Am J Infect Control       Date:  1999-12       Impact factor: 2.918

Review 2.  Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond.

Authors:  S I McFarlane; R Muniyappa; R Francisco; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

3.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 4.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

5.  Fungal flora of the normal human small and large intestine.

Authors:  R Cohen; F J Roth; E Delgado; D G Ahearn; M H Kalser
Journal:  N Engl J Med       Date:  1969-03-20       Impact factor: 91.245

6.  Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation.

Authors:  Christopher P Martin; Robert L Talbert; David S Burgess; Jay I Peters
Journal:  Pharmacotherapy       Date:  2007-01       Impact factor: 4.705

7.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

8.  Growth inhibition of Candida species and Aspergillus fumigatus by statins.

Authors:  Ian G Macreadie; Georgia Johnson; Tanja Schlosser; Peter I Macreadie
Journal:  FEMS Microbiol Lett       Date:  2006-09       Impact factor: 2.742

9.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

10.  Economic impact of Candida colonization and Candida infection in the critically ill patient.

Authors:  P M Olaechea; M Palomar; C León-Gil; F Alvarez-Lerma; R Jordá; J Nolla-Salas; M A León-Regidor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

View more
  9 in total

Review 1.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Statin use and postoperative atrial fibrillation after major noncardiac surgery.

Authors:  Prashant D Bhave; L Elizabeth Goldman; Eric Vittinghoff; Judith H Maselli; Andrew Auerbach
Journal:  Heart Rhythm       Date:  2011-09-09       Impact factor: 6.343

3.  The effect of statin therapy on the incidence of infections: a retrospective cohort analysis.

Authors:  John P Magulick; Christopher R Frei; Sayed K Ali; Eric M Mortensen; Mary Jo Pugh; Christine U Oramasionwu; Kelly R Daniels; Ishak A Mansi
Journal:  Am J Med Sci       Date:  2014-03       Impact factor: 2.378

4.  Effect of Candida albicans on Intestinal Ischemia-reperfusion Injury in Rats.

Authors:  Lei Yan; Chun-Rong Wu; Chen Wang; Chun-Hui Yang; Guang-Zhi Tong; Jian-Guo Tang
Journal:  Chin Med J (Engl)       Date:  2016-07-20       Impact factor: 2.628

5.  The role of Candida albicans SPT20 in filamentation, biofilm formation and pathogenesis.

Authors:  Xiaojiang Tan; Beth Burgwyn Fuchs; Yan Wang; Weiping Chen; Grace J Yuen; Rosalyn B Chen; Elamparithi Jayamani; Cleo Anastassopoulou; Read Pukkila-Worley; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

6.  Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice.

Authors:  Elias A Rahal; Wissam N Constantin; Nabil Zeidan; Alexander M Abdelnoor
Journal:  Front Microbiol       Date:  2015-12-22       Impact factor: 5.640

7.  Association between statins and infections among patients with diabetes: a cohort and prescription sequence symmetry analysis.

Authors:  Koen B Pouwels; Niken N Widyakusuma; Jens H J Bos; Eelko Hak
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-06-30       Impact factor: 2.890

8.  Exposure of Aspergillus fumigatus to Atorvastatin Leads to Altered Membrane Permeability and Induction of an Oxidative Stress Response.

Authors:  Ahmad Ajdidi; Gerard Sheehan; Kevin Kavanagh
Journal:  J Fungi (Basel)       Date:  2020-03-26

9.  Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species.

Authors:  Raimunda Sâmia Nogueira Brilhante; Erica Pacheco de Caetano; Jonathas Sales Oliveira; Débora de Souza Collares Maia Castelo-Branco; Elizabeth Ribeiro Yokobatake Souza; Lucas Pereira de Alencar; Rossana de Aguiar Cordeiro; Tereza de Jesus Pinheiro Gomes Bandeira; José Júlio Costa Sidrim; Marcos Fábio Gadelha Rocha
Journal:  Braz J Infect Dis       Date:  2015-06-26       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.